MedTrace Logo

The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial

NCT00936819 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-08-15

No results posted yet for this study

Summary

This will be the first clinical trial to include a strategy designed to enhance the function of autologous progenitor cells by overexpressing eNOS, and the first to use combination gene and cell therapy for the treatment of cardiac disease.

Conditions

  • Anterior Wall Myocardial Infarction

Interventions

BIOLOGICAL

Plasma-Lyte A and 25% Autologous Plasma

Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

BIOLOGICAL

Autologous EPCs

Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

BIOLOGICAL

Autologous EPCs Transfected with human eNOS

Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Stem Cell Network

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Duncan Stewart, MD, FRCP C · Ottawa Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-19
Primary Completion
2020-03-05
Completion
2029-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936819 on ClinicalTrials.gov